LRMR

Larimar Therapeutics Reports First Quarter 2025 Financial Results

FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval